These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 33462236)

  • 1. Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells.
    Larrue C; Guiraud N; Mouchel PL; Dubois M; Farge T; Gotanègre M; Bosc C; Saland E; Nicolau-Travers ML; Sabatier M; Serhan N; Sahal A; Boet E; Mouche S; Heydt Q; Aroua N; Stuani L; Kaoma T; Angenendt L; Mikesch JH; Schliemann C; Vergez F; Tamburini J; Récher C; Sarry JE
    Nat Commun; 2021 Jan; 12(1):422. PubMed ID: 33462236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CGRP Signaling via CALCRL Increases Chemotherapy Resistance and Stem Cell Properties in Acute Myeloid Leukemia.
    Gluexam T; Grandits AM; Schlerka A; Nguyen CH; Etzler J; Finkes T; Fuchs M; Scheid C; Heller G; Hackl H; Harrer N; Sill H; Koller E; Stoiber D; Sommergruber W; Wieser R
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31756985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and validation of CALCRL-associated prognostic genes in acute myeloid leukemia.
    Huang Z; Zhang H; Xing C; Zhang L; Zhu H; Deng Z; Yin L; Dong E; Wang C; Peng H
    Gene; 2022 Jan; 809():146009. PubMed ID: 34655717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CALCRL induces resistance to daunorubicin in acute myeloid leukemia cells through upregulation of XRCC5/TYK2/JAK1 pathway.
    Tang S; Li S; Shi X; Sheng L; Mu Q; Wang Y; Zhu H; Xu K; Zhou M; Xu Z; Wu A; Ouyang G
    Anticancer Drugs; 2024 Feb; 35(2):163-176. PubMed ID: 37948318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.
    Farge T; Saland E; de Toni F; Aroua N; Hosseini M; Perry R; Bosc C; Sugita M; Stuani L; Fraisse M; Scotland S; Larrue C; Boutzen H; Féliu V; Nicolau-Travers ML; Cassant-Sourdy S; Broin N; David M; Serhan N; Sarry A; Tavitian S; Kaoma T; Vallar L; Iacovoni J; Linares LK; Montersino C; Castellano R; Griessinger E; Collette Y; Duchamp O; Barreira Y; Hirsch P; Palama T; Gales L; Delhommeau F; Garmy-Susini BH; Portais JC; Vergez F; Selak M; Danet-Desnoyers G; Carroll M; Récher C; Sarry JE
    Cancer Discov; 2017 Jul; 7(7):716-735. PubMed ID: 28416471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcitonin Gene-Related Peptide Rescues Proximity Associations of Its Receptor Components, Calcitonin Receptor-Like Receptor and Receptor Activity-Modifying Protein 1, in Rat Uterine Artery Smooth Muscle Cells Exposed to Tumor Necrosis Factor Alpha.
    Dong Y; Chauhan M; Belfort M; Yallampalli C
    Biol Reprod; 2016 Dec; 95(6):126. PubMed ID: 27784654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
    Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
    BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia.
    Angenendt L; Bormann E; Pabst C; Alla V; Görlich D; Braun L; Dohlich K; Schwöppe C; Bohlander SK; Arteaga MF; Wethmar K; Hartmann W; Angenendt A; Kessler T; Mesters RM; Stelljes M; Rothenberg-Thurley M; Spiekermann K; Hébert J; Sauvageau G; Valk PJM; Löwenberg B; Serve H; Müller-Tidow C; Lenz G; Wörmann BJ; Sauerland MC; Hiddemann W; Berdel WE; Krug U; Metzeler KH; Mikesch JH; Herold T; Schliemann C
    Leukemia; 2019 Dec; 33(12):2830-2841. PubMed ID: 31182782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcitonin receptor-like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML.
    Angenendt L; Wöste M; Mikesch JH; Arteaga MF; Angenendt A; Sandmann S; Berdel WE; Lenz G; Dugas M; Meshinchi S; Schliemann C; Rössig C
    Blood Adv; 2021 Nov; 5(21):4413-4421. PubMed ID: 34559198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
    Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
    Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular effects of exogenous adrenomedullin and CGRP in Ramp and Calcrl deficient mice.
    Pawlak JB; Wetzel-Strong SE; Dunn MK; Caron KM
    Peptides; 2017 Feb; 88():1-7. PubMed ID: 27940069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcitonin gene-related peptide receptor Calcrl is enriched in hair follicles stem cells and differentially expressed in interfollicular epidermis in murine skin.
    Gong Y; Wei JP; Wang TH; Zhong HB; Liao XH
    Neuroreport; 2020 Aug; 31(11):814-818. PubMed ID: 32576770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the Calcitonin Receptor-like Receptor (CALCRL) in Normal and Neoplastic Tissues.
    Wende B; Beyer AL; Ruhnke N; Kaemmerer D; Sänger J; Schulz S; Lupp A
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy.
    Cartel M; Mouchel PL; Gotanègre M; David L; Bertoli S; Mansat-De Mas V; Besson A; Sarry JE; Manenti S; Didier C
    Leukemia; 2021 Feb; 35(2):417-432. PubMed ID: 32447346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic lethality of combined AT-101 with idarubicin in acute myeloid leukemia via blockade of DNA repair and activation of intrinsic apoptotic pathway.
    Yang Q; Chen K; Zhang L; Feng L; Fu G; Jiang S; Bi S; Lin C; Zhou Y; Zhao H; Chen XL; Fu G; Xu B
    Cancer Lett; 2019 Oct; 461():31-43. PubMed ID: 31301319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extinguishing the Embers: Targeting AML Metabolism.
    Culp-Hill R; D'Alessandro A; Pietras EM
    Trends Mol Med; 2021 Apr; 27(4):332-344. PubMed ID: 33121874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of Receptor Activity-Modifying Protein 3 (RAMP3) in the Vascular Actions of Adrenomedullin in Rat Mesenteric Artery Smooth Muscle Cells.
    Chauhan M; Yallampalli U; Banadakappa M; Yallampalli C
    Biol Reprod; 2015 Nov; 93(5):116. PubMed ID: 26423127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML Recurrence.
    Boyd AL; Aslostovar L; Reid J; Ye W; Tanasijevic B; Porras DP; Shapovalova Z; Almakadi M; Foley R; Leber B; Xenocostas A; Bhatia M
    Cancer Cell; 2018 Sep; 34(3):483-498.e5. PubMed ID: 30205048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.
    Daga S; Rosenberger A; Quehenberger F; Krisper N; Prietl B; Reinisch A; Zebisch A; Sill H; Wölfler A
    Cancer Med; 2019 Apr; 8(4):1771-1778. PubMed ID: 30848055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXM1 contributes to treatment failure in acute myeloid leukemia.
    Khan I; Halasi M; Patel A; Schultz R; Kalakota N; Chen YH; Aardsma N; Liu L; Crispino JD; Mahmud N; Frankfurt O; Gartel AL
    JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.